Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2017

01-07-2017 | Brief Research Article

Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy

Authors: L. de la Cueva, P. Lloro, M. J. Sangrós, L. López Vélez, P. Navarro, L. Sarria, S. Álvarez, D. Abós

Published in: Clinical and Translational Oncology | Issue 7/2017

Login to get access

Abstract

Purpose

To describe the frequency of head and/or pancreas uncinate process uptake of 99mTc-HYNIC-TOC, to study its nature, and analyze its diagnostic value.

Materials and methods

Retrospective evaluation of 47 consecutive 99mTc-HYNIC-TOC examinations was conducted. Head and/or pancreas uncinate process uptake was considered to be physiological in patients with normal CT at the same episode and in follow-up. It was analyzed if age or diabetes mellitus was justifying the existence or not of uptake.

Results

32.5% patients showed uptake; 73% of them were mild. 84.6% patients with uptake have no pathology and 4% had neuroendocrine pancreatic disease at CT. Neither the age nor the diabetes mellitus established differences in patients without lesion.

Conclusions

Near one-third of patients show physiological uptake by head and/or pancreas uncinate process at 99mTc-HYNIC-TOC scintigraphy. It seems that neither the diabetes nor the ages are factors that determine this physiological uptake.
Literature
1.
Bangard M, Béhé M, Bender H, Guhlke S, Willkomm P, Risse J, et al. Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results [abstract]. Eur J Nucl Med. 1998;25:837.CrossRef
2.
Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new [99mTc]-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111 in-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27:628–37.CrossRefPubMed
3.
Hubalewska-Dydejczyk A, Fröss-Baron K, Mikołajczak R, Maecke HR, Huszno B, Pach D, et al. [99mTc]-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years experience. Eur J Nucl Med Mol Imaging. 2006;33:1123–33.CrossRefPubMed
4.
Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative analysis and characterization of physiological biodistribution of (68) Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2012;37:1052–7.CrossRefPubMed
5.
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls and pitfalls in interpretation. RadioGraphics. 2015;35:500–16.CrossRefPubMed
6.
Mapelli P, Tam HH, Sharma R, Aboagye EO, Al-Nahhas A. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging. Nucl Med Commun. 2014;35:613–9.CrossRefPubMed
7.
Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37:57–62.CrossRefPubMed
8.
Castellucci P, Ucha JP, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52:886–90.CrossRefPubMed
9.
Jacobsson H, Larsson P, Jonsson C, Jussing E, Grybäck P. Normal uptake of 68Ga-DOTA-TOC by the pancreas uncinate process mimicking malignancy at somatostatin receptor PET. Clin Nucl Med. 2012;37:362–5.CrossRefPubMed
10.
Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179–84.CrossRefPubMed
11.
Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.CrossRefPubMed
12.
Yamaga LY, Neto GC, da Cunha ML, Osawa A, Oliveira JC, Fonseca RQ, et al. [99mTc]-HYNIC-TOC increased uptake can mimic malignancy in the pancreas uncinate process at somatostatin receptor SPECT/CT. Radiol Med. 2016;121:225–8.CrossRefPubMed
13.
Koçyiğit Deveci E, Ocak M, Bozkurt MF, Türker S, Kabasakal L, Uğur O. The diagnostic efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in comparison with 111 in-pentetrotide in the detection of neuroendocrine tumours. Mol Imaging Radionucl Ther. 2013;22:76–84.CrossRefPubMedPubMedCentral
14.
Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111 in-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708–16.PubMed
15.
Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: monodose evaluation and comparison with 111 in-octreotide. J Nucl Med. 2000;41:114–9.
16.
Sako T, Hasegawa K, Nishimura M, Kanayama Y, Wada Y, Hayashinaka E, et al. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement. Biochem Biophys Res Commun. 2013;442:79–84.CrossRefPubMed
17.
Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10:S23–9.CrossRefPubMed
18.
Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE1, Reubi JC, Kwekkeboom DJ, Krenning EP. Gastroenterology. 2010;139:742–53.CrossRefPubMed
19.
20.
Unger N, Ueberberg B, Schulz S, Saeger W, Mann K, Petersenn S. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous normal human tissues. Exp Clin Endocrinol Diabetes. 2012;120:482–9.CrossRefPubMed
21.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes of radiotracers selected for scintigraphic and radiotherapeutic somatostatin SST1-SST5 use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed
22.
Kunikowska J, Królicki L. PET receptor imaging in clinical oncology. Nucl Med Rev. 2012;15:C61–3.CrossRef
23.
Gandomkar M, Najafi R, Rabbani M. 99mTc-EDDA-Tricine-HYNIC-TOC versus 99mTc-EDDA-Tricine-HYNIC-TATE: synthesis and monodose result of two new radiopharmaceuticals for somatostatin receptor scintigraphy. International Atomic Energy Agency, Division of Physical and Chemical Sciences and Division of Human Health, Vienna (Austria); 2005. p. 348, 180; ISTR-2005: International symposium on trends in radiopharmaceuticals; Vienna (Austria); 14–18 Nov 2005; IAEA-CN-130; IAEA-CN-130/096P.
24.
Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80–7.CrossRefPubMed
25.
O’Sullivan AW, Heaton N, Rela M. Cancer of the uncinate process of the pancreas: surgical anatomy and clinicopathological features. Hepatobiliary Pancreat Dis Int. 2009; 8(6):569–74.
26.
Gersell DJ, Gingerich RL, Greider MH. Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes. 1979;28:11–5.CrossRefPubMed
27.
Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126–32.PubMed
28.
Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological and pathological processes in PET/CT uptake. Eur J Nucl Med Mol Imaging. 2013;40:514–23.CrossRefPubMed
29.
Prasad V, Baum PR. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumour lesions. Q J Nucl Med Mol Imaging. 2010;54:61–7.PubMed
30.
Metadata
Title
Physiological expression of pancreatic somatostatin receptors in 99mTc-HYNIC-TOC scintigraphy
Authors
L. de la Cueva
P. Lloro
M. J. Sangrós
L. López Vélez
P. Navarro
L. Sarria
S. Álvarez
D. Abós
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1616-3

Other articles of this Issue 7/2017

Clinical and Translational Oncology 7/2017 Go to the issue

Research Article

Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer

Research Article

Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma

Research Article

Circulating levels of autoantibodies against L1-cell adhesion molecule as a potential diagnostic biomarker in esophageal squamous cell carcinoma

Review Article

Retroperitoneal lymph node dissection: an update in testicular malignancies

Research Article

Effects of low-dose radiation on adaptive response in colon cancer stem cells

Research Article

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits